While targeted TKI therapies (BCR-ABL antagonists) have resulted in improved survival of patients with CP CML, the prevalence of CML doubled in the U.S. between 2001 and 2009 (http://seer.cancer.gov/). Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.